Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 7/20 | 0.34 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15156214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL8442314 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2389036 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL15326061 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL10000307 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL23560381 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL2725276 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL6515101 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL22277214 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB | |
| SCHEMBL19462783 | 1.00 | CES2 (0.41) | CES2LPAR1LPAR3TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | claimed |
| US-20240392094-A1 | Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition | LG CHEM, LTD. (KR) | 2024-11-28 | — | — | US | claimed |
| US-20240350425-A1 | COMPOSITIONS COMPRISING MIXTURES OF SEMIFLUORINATED ALKANES | NOVALIQ GMBH (DE) | 2024-10-24 | — | — | US | claimed |
| US-12005033-B2 | Compositions comprising mixtures of semifluorinated alkanes | NOVALIQ GMBH (DE) | 2024-06-11 | — | — | US | claimed |
| CN-117897439-A | Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition | 株式会社LG化学 | 2024-04-16 | — | — | CN | claimed |
| WO-2023033605-A1 | METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| WO-2023033601-A1 | METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION | 주식회사 엘지화학 | 2023-03-09 | — | — | WO | claimed |
| US-12569452-B2 | Ophthalmic compositions comprising F6H8 | NOVALIQ GMBH (DE) | 2026-03-10 | — | — | US | disclosed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20240392094-A1 | Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition | LG CHEM, LTD. (KR) | 2024-11-28 | — | — | US | disclosed |
| US-20240350425-A1 | COMPOSITIONS COMPRISING MIXTURES OF SEMIFLUORINATED ALKANES | NOVALIQ GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| US-20240245625-A1 | OPTHALMIC COMPOSITIONS COMPRISING F6H8 | NOVALIQ GMBH (DE) | 2024-07-25 | — | — | US | disclosed |
| US-12005033-B2 | Compositions comprising mixtures of semifluorinated alkanes | NOVALIQ GMBH (DE) | 2024-06-11 | — | — | US | disclosed |
| US-20130048913-A1 | LIQUID CRYSTAL COMPOUND HAVING PERFLUOROALKYL CHAIN, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-2110126-B9 | Inhalative and instillative use of semi-fluorised alkanes as active ingredient carriers in the intrapulmonary area | NOVALIQ GMBH (DE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2110126-B1 | Inhalative and instillative use of semi-fluorised alkanes as active ingredient carriers in the intrapulmonary area | NOVALIQ GMBH (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20100291679-A1 | COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION | 2010-11-18 | — | — | US | disclosed |
| EP-1974013-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | Anthrogenesis Corporation (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | Celularity, Inc. | 2007-08-16 | — | — | US | disclosed |
| WO-2007079185-A2 | IMPROVED COMPOSITION FOR COLLECTING AND PRESERVING PLACENTAL STEM CELLS AND METHODS OF USING THE COMPOSITION | ANTHROGENESIS CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048913-A1 | LIQUID CRYSTAL COMPOUND HAVING PERFLUOROALKYL CHAIN, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | FFAR2, RCC2, NPFFR2 | CES2 361/4885LPAR1 90/4885LPAR3 103/4885 |
| US-12569452-B2 | Ophthalmic compositions comprising F6H8 | F8, CFH, FAAH2 | CES2 1666/4885LPAR1 1236/4885LPAR3 835/4885 |
| US-20070190042-A1 | Composition for collecting and preserving placental stem cells and methods of using the composition | PGF, ALPP, CPA1 | CES2 225/4885LPAR1 2392/4885LPAR3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.